What happened

Jay Vandegriff, an Idaho resident, is suing Novo Nordisk over vision loss he alleges was caused by Ozempic, according to reports quoting him and his lawyer. He says he began treatment for type 2 diabetes in 2023. The company disputes the personal injury claims and says a causal relationship between semaglutide and the condition has not been established.S1S2

Vandegriff says he noticed a smudge in his left eye on Christmas Day 2024 and was subsequently diagnosed with non-arteritic anterior ischaemic optic neuropathy, or NAION. He describes continuing deterioration after stopping treatment and difficulty working and judging distances. These are his accounts of his symptoms and their effects.S1S2

His lawyer, Danielle Gold of Weitz & Luxenberg, says the firm has filed more than 100 cases, with another 100 to 150 pending in New Jersey Superior Court through other firms. She says Vandegriff seeks compensation for an alleged failure to warn. Those figures are the lawyer's account of the litigation.S1

Why it matters

On 9 November, the FDA required warnings about a potential increased risk of NAION across GLP-1 receptor agonist medicines. Its safety communication describes a rare condition that can cause permanent sight loss. The warning concerns a possible treatment risk; it does not decide what caused Vandegriff's individual injury or whether the manufacturer is liable.R1S1S2

Novo Nordisk told the Manchester Evening News that it considers the US personal injury lawsuits without merit and is defending them. It said it continues to assess clinical, epidemiological and post-marketing evidence. That is the company's position, alongside the plaintiffs' allegation that they were inadequately warned.S2

The background

The UK's MHRA issued semaglutide safety advice on 5 February 2026, describing the possible association with NAION as very rare. It explains that reduced blood flow to the optic nerve causes the condition and that type 2 diabetes itself increases the underlying risk. That background complicates attribution of an individual case.R2

New Jersey's Supreme Court designated the NAION claims as a separate multicounty litigation, assigning centralised management to Bergen County. A November 2025 court notice distinguishes these vision-loss cases from gastrointestinal-injury claims involving the same drug class. The document concerns case management, rather than findings on the merits of individual claims.R3

What happens next

The outcome of Vandegriff's claim remains unresolved in the material reviewed. For patients, the MHRA advises urgent attendance at eye casualty or A&E for sudden sight loss or rapidly worsening vision during semaglutide treatment. The FDA says patients who have experienced NAION should discuss continuing or stopping treatment with their clinician.S1S2R1R2